James Allison

Co-Founder at Jounce Therapeutics, Inc.

James Allison

James Allison

Co-Founder at Jounce Therapeutics, Inc.

Overview
Career Highlights

University of Texas - MD Anderson Cancer Center
Jounce Therapeutics, Inc.
Neon Therapeutics, Inc.

RelSci Relationships

5133

Number of Boards

14

Number of Awards

2

Relationships
RelSci Relationships are individuals James Allison likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Jounce Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

Head of Immunology at Fred Hutchinson Cancer Research Center

Relationship likelihood: Strong

Head, Division of Cancer Medicine at University of Texas - MD Anderson Cancer Center

Relationship likelihood: Strong

Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Former Director, Laboratory of Genetics at The Salk Institute for Biological Studies

Relationship likelihood: Strong

Co-Founder at Tango Therapeutics, Inc.

Relationship likelihood: Strong

Lloyd J. Old-Virginia & Daniel K. Ludwig Chair in Clinical Investigation, Chief, Melanoma & Immunotherapeutics Service, Director, Parker Institute for Cancer Immunotherapy, Msk & Associate Director, Ludwig Center for Cancer Immunotherapy at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Member, Cancer Immunology Program at The Tisch Cancer Institute - Icahn School of Medicine at Mount Sinai

Relationship likelihood: Strong

Vice President, Cancer Immunology at Genentech, Inc.

Relationship likelihood: Strong

Paths to James Allison
Potential Connections via
Relationship Science
You
James Allison
Co-Founder at Jounce Therapeutics, Inc.
Education
Ph.D. in Biological Sciences
Class of 1973

The University of Texas at Austin is one of the largest public universities in the United States and is the largest institution of The University of Texas System. Founded in 1883, the university has grown from a single building, eight teachers, two departments and 221 students to a 350-acre main campus with 17 colleges and schools, about 24,000 faculty and staff, and more than 50,000 students.

Memberships
Member
Current

The National Academy of Sciences (NAS) formed the Committee on International Security and Arms Control (CISAC) in 1980 as a permanent committee to bring the resources of the Academy to bear on critical problems of international security and arms control. CISAC, in the Policy and Global Affairs Division, draws from the nation’s finest scientific, technical, engineering and medical talent to advise the government, contribute to the work of non-governmental organizations, and inform the public about scientific and technical issues related to international security and arms control. CISAC’s work benefits from a rotating membership of distinguished scientists, policy and military experts. The Committee carries out its mandate through a variety of activities that receive financial support from public and private sponsors.

Fellow
Current

The American Association for the Advancement of Science provides science related journal, program, and education services. The firm also promotes the responsible use of science in public policy. The company was founded in 1848 and is headquartered in Washington, DC.

Member
Current

The Institute of Medicine (IOM) is an independent, nonprofit organization that works outside of government to provide unbiased and authoritative advice to decision makers and the public. Established in 1970, the IOM is the health arm of the National Academy of Sciences, which was chartered under President Abraham Lincoln in 1863. Nearly 150 years later, the National Academy of Sciences has expanded into what is collectively known as the National Academies, which comprises the National Academy of Sciences, the National Academy of Engineering, the National Research Council, and the IOM.

Career History
Co-Founder
2013 - Current

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Co-Founder
2013 - Current

Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

Executive Director, Immunotherapy Platform
Current

The University of Texas MD Anderson Cancer Center is one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is located in central Houston in the Texas Medical Center. MD Anderson was created in 1941 as part of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 68 National Cancer Institute-designated comprehensive cancer centers today. U.S. News & World Report’s "Best Hospitals" survey has ranked MD Anderson as one of the nation’s top two cancer centers every year since the survey began in 1990.

Boards & Committees
Member, Scientific Advisory Panel
Current

The Melanoma Research Alliance (MRA) is the largest non-profit funder of melanoma research. Since its founding in 2007, MRA has committed $100 million in funding to advance our understanding of this disease. MRA funds projects in the areas of prevention, diagnosis, and treatment, with the majority of funding allocated for melanoma treatment.

Investments
Details Hidden

Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

Details Hidden

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Awards & Honors
Breakthrough Prize in Life Sciences
Lasker-DeBakey Clinical Medical Research Award
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by James Allison. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of James Allison's profile does not indicate a business or promotional relationship of any kind between RelSci and James Allison.